Stockscreener 앱 받기
4.00
3.63%
0.14
전일 마감가:
$3.86
열려 있는:
$3.93
하루 거래량:
2.91M
Relative Volume:
3.50
시가총액:
$305.86M
수익:
$114.70K
순이익/손실:
$-26.49M
주가수익비율:
-1.6217
EPS:
-2.4665
순현금흐름:
$-53.17M
1주 성능:
+18.34%
1개월 성능:
+12.36%
6개월 성능:
+1.27%
1년 성능:
+124.72%
1일 변동 폭
$3.85
$4.10
1주일 범위
$3.325
$4.19
52주 변동 폭
$1.67
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
4.00 | 305.86M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-19 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting - Investing.com UK
SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart
SAB Biotherapeutics Shareholders Back Board and Auditor - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) investors back board slate and auditor - Stock Titan
SAB Biotherapeutics Inc (SABS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SAB Biotherapeutics Inc (SABSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SAB Biotherapeutics Inc (SABSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
SAB Biotherapeutics Inc (SABSW) Institutional Confidence - TradingKey
SABS Maintained by Chardan Capital -- Price Target Raised to $16 - GuruFocus
SAB Biotherapeutics Inc (SABSW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jefferies raises SAB Biotherapeutics price target on FDA approval By Investing.com - Investing.com South Africa
SABS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
SABSW Warrants Trade Near Par Value as SAB Biotherapeutics Warrants Hold SteadySell Signal Alerts - newsline.com
SABS Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsCFO Commentary Report - newsline.com
SAB Biotherapeutics, Inc. (SABS) Presents at FOCIS 2026 Annual MeetingSlideshow (NASDAQ:SABS) 2026-06-10 - Seeking Alpha
SAB Biotherapeutics (SABS) Edges Lower, Holds Above Key Support Amid Biotechnology Sector CautionSmall Cap Breakouts - newsline.com
Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans? - Sahm
Going beyond insulin in type 1 diabetes: A new wave of disease-modifying therapies - statnews.com
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
SABS - Finviz
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at Upcoming ADA and FOCIS Congresses - Quiver Quantitative
Potential T1D immunotherapy SAB-142 to feature at two June medical meetings - Stock Titan
SABS Technical Analysis & Stock Price Forecast - Intellectia AI
SAB Biotherapeutics (SABS) Slides 3.81% as Biotech Sector Faces Headwinds; Key Support TestedStock Surge Alerts - The Legal Advocate
SABS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Citi Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11 - Moomoo
Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues Development; Shares Edge HigherFinancial Health Score - Newser
Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target - marketscreener.com
Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Initiated Coverage by Jefferies -- Rating Set to Buy - GuruFocus
Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target - Moomoo
Jefferies initiates SAB Biotherapeutics stock with buy on diabetes therapy potential - Investing.com Australia
SAB Biotherapeutics Q1 earnings call highlights - MSN
Why Is SAB Biotherapeutics, Inc. (SABSW) Stock Up Today? - Meyka
SAB Biotherapeutics (SABS) Q1 2026 Miss: What Went WrongCore Business Growth - Newser
Number of shareholders of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):